Is the prophylactic antidepressant efficacy of lithium in bipolar I disorder dependent on study design and lithium level?

Journal of Clinical Psychopharmacology

Volumn 25, Issue 5, 2005, Pages 457-462

  Severus, Wolfram Emanuel ^a   Grunze, Heinz ^a   Kleindienst, Nikolaus ^a   Frangou, Sophia ^b   Moeller, Hans Juergen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE; LITHIUM; OLANZAPINE; PLACEBO; VALPROIC ACID;

ADD ON THERAPY; BIPOLAR I DISORDER; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; EVIDENCE BASED MEDICINE; HUMAN; MAINTENANCE THERAPY; MANIA; METHODOLOGY; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REVIEW;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; HUMANS; LITHIUM; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TRIAZINES;

EID: 25444512702     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000177550.13714.7a     Document Type: Review

References (25)

1. Kleindienst N, Greil W. Lithium in the long-term treatment of bipolar disorders. Eur Arch Psychiatry Clin Neurosci. 2003;253:120-125.
2. Calabrese JR, Vieta E, El Mallakh R, et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry. 2004;56:957-963.
3. Prien RF, Klett CJ, Caffey EM. Lithium prophylaxis in recurrent affective illness. Am J Psychiatry. 1974;131:198-203.
4. Prien RF, Caffey EM, Klett CJ. Prophylactic efficacy of lithium carbonate in manic depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry. 1973;28:337-341.
5. Prien RF, Klett CJ, Caffey EM. Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch Gen Psychiatry. 1973;29:420-425.
6. Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161:217-222.
7. Gelenberg AJ, Pies R. Matching the bipolar patient and the mood stabilizer. Ann Clin Psychiatry. 2003;15:203-216.
8. Perlis RH, Sachs GS, Lafer B, et al. Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data. Am J Psychiatry. 2002;159:1155-1159.
9. Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med. 1989;321:1489-1493.
10. Himmelhoch JM, Neil JF. Lithium therapy in combination with other forms of treatment. In: Johnson FN, ed. Handbook of Lithium Therapy. Lancaster, UK: MTP Press; 1980;7:60.
11. Nilsson A, Axelsson R. Psychopathology during long-term lithium treatment of patients with major affective disorders. A prospective study. Acta Psychiatr Scand. 1989;80:375-388.
12. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000;57:481-489,
13. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60:392-400.
14. Calabrese J, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:1013-1024.
15. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005;162:1281-1290.
16. Ahmed S, Lipkovich I, Healy K, et al. Comparison of olanzapine and lithium treatment groups based on lithium blood levels: a 52-week bipolar relapse prevention study. Presented at: New Clinical Drug Evaluation Unit Program (NCDEU) meeting. June 1-4, 2004. Phoenix, AZ.
17. Baldessarini RJ, Tohen M, Tondo L. Maintenance treatment in bipolar disorder. Arch Gen Psychiatry. 2000;57:490-492.
18. Tohen M, Bowden C, Calabrese J, et al. Olanzapine's efficacy for relapse prevention in bipolar disorder: a randomized double-blind placebo-controlled 12-month clinical trial. Bipolar Disord. 2003;6:89.
19. Practice guideline for the treatment of patients with bipolar disorder [revision]. Am J Psychiatry. 2002;159:1-50.
20. Baastrup PC, Poulsen JC, Schou M, et al. Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet. 1970;2:326-330.
21. Maj M, Starace F, Nolfe G, et al. Minimum plasma lithium levels required for effective prophylaxis in DSM III bipolar disorder: a prospective study. Pharmacopsychiatry. 1986;19:420-423.
22. Stoll AL, Tohen M, Baldessarini RJ, et al. Shifts in diagnostic frequencies of schizophrenia and major affective disorders at six North American psychiatric hospitals. 1972-1988. Am J Psychiatry. 1993;150:1668-1673.
23. Grof P, Aida M. Discrepancies in the efficacy of lithium. Arch Gen Psychiatry. 2000;57:191.
24. Moncrieff J. A re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder. Br J Psychiatry. 1995;167:569-574.
25. Pies R. Have we undersold lithium for bipolar disorder? J Clin Psychopharmacol. 2002;22:445-449.